Treatment of anti-HMGCR myopathy appears to be safer and more efficacious if commenced early, perhaps due to lower doses and durations of immunosuppressant required, and more minimal inflammation in the early stages of diseases [18]. The gene discussed is HMGCR; the disease is myopathy.